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Abstract
Personalized medicine requires the integration and processing of vast amounts of data. Here, we propose a
solution to this challenge that is based on constructing Digital Twins. These are high-resolution models of
individual patients that are computationally treated with thousands of drugs to find the drug that is optimal for the
patient.
Background
Despite great strides in biomedical advances during the
past century, a large number of patients do not respond to
drug treatment. According to a report from the US Food
and Drug Administration (FDA), medication is deemed
ineffective for 38–75% of patients with common diseases
[1]. This results in patient suffering and increased health-
care costs. These problems reflect the complexity of com-
mon diseases, which may involve altered interactions
between thousands of genes that differ between patients
with the same diagnosis. There is a wide gap between this
complexity and modern health care, in which diagnostics
often relies on a small number of biomarkers of limited
sensitivity or specificity. Digital and genomic medicine
may bridge this gap by monitoring, processing, and inte-
grating vast amounts of data from wearable digital devices,
omics, imaging, and electronic medical records [2]. How-
ever, the integration and clinical exploitation of such com-
plex data are unresolved challenges.
Application of the digital twin concept to
personalize medicine
Digital twins are a concept from engineering which has
been applied to complex systems such as airplanes or even
cities [3]. The aims are to model those systems computa-
tionally, in order to develop and test them more quickly
and economically than is possible in the real-life setting.
Ideally, the digital twin concept can be translated to
patients in order to improve diagnostics and treatment.
This is the general aim of the DigiTwin consortium, which
includes academic, clinical and industrial partners from 32
countries (https://www.digitwins.org). Practical and scalable
solutions for specific problems will also require national ini-
tiatives. As an example, the Swedish Digital Twin Consor-
tium (SDTC) aims to develop a strategy for personalized
medicine (https://www.sdtc.se). The SDTC strategy, which
is the focus of this Comment, is based on: (i) constructing
unlimited copies of network models of all molecular,
phenotypic, and environmental factors relevant to disease
mechanisms in individual patients (i.e., digital twins); (ii)
computationally treating those digital twins with thousands
of drugs in order to identify the best performing drug; and
(iii) treating the patient with this drug (Fig. 1).
Clinical implementation of this strategy has presented
questions that must be addressed: Which information is
needed? How can it be integrated and analyzed? If we start
with the molecular changes, these are dispersed across an
unknown number of cell types in the body. A recent study
indicated that 50% of 45 analyzed cell types were involved
in each of more than 100 diseases [4]. Can we analyze all
those cell types simultaneously in patients? If we look at
an inflammatory disease, rheumatoid arthritis, many of
the cell types are located in tissues that are difficult to ob-
tain from patients, such as the liver or lungs. However, it
is possible to perform multi-omics analyses of individual
cells from even small quantities of any fluid or tissue that
can be obtained from the body. For example, single-cell
RNA-sequencing (scRNA-seq) has been used to profile
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the mRNA in thousands of cells in many diseases. This
has already resulted in the identification of novel mecha-
nisms that can potentially be exploited for personalized
medicine [5, 6]. However, the complexity of those mecha-
nisms makes drug prioritization a formidable challenge.
For example, scRNA-seq analysis of inflammatory and
malignant diseases implicated hundreds of drugs, many of
which targeted mechanisms that did not overlap [4]. Thus,
targeting one mechanism may not be effective. How can
we integrate and analyze all the data derived from scRNA-
seq to prioritize mechanisms for drug treatment?
Network tools to construct and exploit digital
twins for personalized medicine
A large body of evidence suggests that complex systems
can be described and analyzed by network tools. In the
context of medicine, protein–protein interaction (PPI)
networks can be used as templates, to which disease-
associated genes can be mapped [7, 8].
Such variables tend to co-localize and form modules
which contain the genes that are most important for
pathogenesis, diagnostics, and therapeutics [8]. Other
network tools can be applied to prioritize individual
genes in a module. For example, the most intercon-
nected, or central, nodes tend to be most important. We
propose that the same methods can be applied to con-
struct digital twins of individual patients.
Expanding digital twins by integrating variables
of multiple types, locations, and time points
A digital twin should ideally integrate all of the types of
variable that are relevant to pathogenesis. If the variables
are different types of molecules, these can be mapped on
the PPI network in order to form multilayer modules [8].
Consider, for example, one module formed by mRNAs and
another formed by genes harboring disease-associated vari-
ants. If the mRNAs and genes map to the same proteins,
the two modules can be linked. The same principle can be
Fig. 1 The digital twin concept for personalized medicine. a An individual patient has a local sign of disease (red). b A digital twin of this patient
is constructed in unlimited copies, based on computational network models of thousands of disease-relevant variables. c Each twin is
computationally treated with one or more of the thousands of drugs. This results in digital cure of one patient (green). d The drug that has the
best effect on the digital twin is selected for treatment of the patient
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applied to integrate many other types of molecules, such as
mRNAs or proteins.
The multilayer modules can be used to form and test
hypotheses, which may have direct implications for
translating diagnostics and the treatment of a digital
twin to patient care. For example, if a disease-associated
single nucleotide polymorphism (SNP) causes the altered
expression of a protein in a twin, this would lead to in
silico treatment with a drug that specifically blocks that
protein. If successful, this could, in turn, motivate diag-
nostic measurement of the protein in the patient. If the
protein level is elevated, the patient would be treated
with the same drug.
However, diagnostic and therapeutic decisions generally
need to consider multiple types of data other than mole-
cules, such as symptoms or environmental factors, which
means that the digital twin concept cannot be restricted
to molecular profiles. As an example, in severe asthma, a
combination of allergen avoidance and medication may be
needed. An important advantage of multilayer modules is
that they can potentially integrate molecular modules with
modules representing other types of disease-relevant data.
For example, symptoms from multiple diseases can be
linked into a network that is based on co-occurrence, and
form modules (that represent wheezing and coughing in
asthma). Such phenotypic modules can be linked to their
corresponding molecular modules [7, 8]. With increasing
availability of multi-omics, phenotypic, and environmental
data, network tools may allow the construction of disease
models of unprecedented resolution. Such models may
serve as templates for the construction of digital twins for
individual patients.
Network tools can also be used to link interactions be-
tween cell types in different tissues. For example, cells in
an arthritic joint may interact with cells in adjacent lymph
nodes through different mediators [4]. Thus, multicellular
network models from different tissues may be linked into
a meta-network of interacting models, thereby generating
comprehensive digital twins. Network tools, such as cen-
trality, can then be applied to prioritize the most import-
ant tissues, cell types, and genes. This is important
because causal mechanisms may reside in tissues other
than those that cause symptoms. For example, in rheuma-
toid arthritis, the lungs have been proposed to have such a
role and might be more suitable for therapeutic targeting
than joints. The same principles can be applied to link tis-
sues and cells over time [9]. This is important because
many diseases evolve over many years before symptoms
and diagnosis occur, by which time treatment may be un-
successful because of irreversible tissue damage. There-
fore, early diagnosis and treatment are important. Taken
together, network tools may be exploited to construct
high-resolution twins that enable the prioritization of bio-
markers and drug targets for personalized medicine, even
if the causal cell types are not accessible for analysis. It is
also important to recognize that other methods, such as
machine learning and artificial intelligence, can be used
complementarily to construct and analyze digital twins.
Examples include modeling the development of the net-
works over time or predicting the optimal treatments
from the network structures. In this scenario, the digital
twin model can be considered as an artificial intelligence
system that interacts with the drugs and experiences the
changes that occur in the human body. Various machine-
learning tools, such as Bayesian Networks, Deep Learning,
Decision Trees, Causal Inference, or State-Space models,
may be needed [10].
Conclusions
The clinical implementation of digital twins will require
solving a wide range of technical, medical, ethical, and
theoretical challenges. The costs and complexity will be
comparable to those of projects such as the Human
Genome Project (HGP), but may lead not only to greatly
improved health care and understanding of disease
mechanisms but also to completely new research direc-
tions. Another potential similarity to HGP could be the
potential to inspire technical developments, leading to a
decrease in both the costs and the difficulties involved in
clinically implementing digital twins. Given the import-
ance of the medical problem, the potential of digital
twins merits concerted research efforts on a scale similar
to those involved in the HGP.
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